剂量学对HDR前列腺近距离治疗单药疗效的影响
该回顾性研究纳入2005–2013年接受HDR近距离治疗单药的286例局限期前列腺癌患者,分析EQD2 D90、V100、V150和DHI与生化复发及总生存的关系。中位随访108–120个月,10年bRFI为72.8%、OS为78.3%;整体队列中EQD2 D90与bRFI或OS无关联,仅2次分割亚组中较高EQD2 D90与OS改善相关。
要点
- 整体队列中EQD2 D90、V100、V150及DHI均与bRFI或OS无显著关联。
- 10年bRFI为72.8%,10年OS为78.3%,中位随访108–120个月。
- 仅2次分割亚组中较高EQD2 D90与OS改善相关,1次和3次分割亚组未见。
核心结论
- 在局限期前列腺癌HDR近距离治疗单药患者中,提高EQD2 D90与bRFI或OS改善无关联。
- 在已达到的较高且较窄剂量范围内,一旦靶区覆盖充分,进一步增加D90可能获益有限,但不意味着不同分割方案等效。
研究设计与样本
- 回顾性分析286例连续接受HDR近距离治疗单药的局限期前列腺癌患者,治疗时间为2005–2013年。
- 分割方案包括19–20 Gy×1、13 Gy×2或10.5 Gy×3。
- 剂量学参数包括EQD2 D90、V100、V150和剂量均匀性指数(DHI)。
- 采用Kaplan-Meier法估计生化无复发生存间期(bRFI)和总生存(OS),Cox回归评估EQD2 D90与结局的关联。
主要发现
- bRFI中位随访108个月,OS中位随访120个月。
- 10年bRFI率为72.8%,10年OS率为78.3%。
- 整体队列中EQD2 D90与bRFI或OS无关联,V100、V150和DHI亦与临床结局无关联。
- 亚组分析中,EQD2 D90在任何分割方案中均与bRFI无关联。
- 较高EQD2 D90与2次分割亚组OS改善相关,但在1次或3次分割亚组中未见此关联。
临床怎么用
- 在HDR近距离治疗单药中,达到充分靶区覆盖后,不应仅以进一步提高D90作为改善生化控制的策略。
- 不同分割方案的剂量学参数与结局关系可能不同,2次分割亚组中EQD2 D90与OS的关联需进一步验证。
局限性
- 本研究为回顾性分析,样本来自单一系列,可能存在选择偏倚。
- 所达到的剂量范围相对较高且较窄,可能限制了对剂量效应的检测。
- 作者指出需进一步研究验证这些发现并优化HDR近距离治疗的剂量投放。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the association between brachytherapy dose and oncological outcomes in patients with localized prostate cancer treated with high-dose-rate (HDR) brachytherapy monotherapy. METHODS: We retrospectively analyzed 286 consecutive patients treated with HDR brachytherapy monotherapy (19-20 Gy × 1, 13 Gy × 2, or 10.5 Gy × 3) between 2005 and 2013. Dosimetric parameters included the equivalent dose in 2-Gy fractions covering 90% of the planning target volume (EQD2 D90), V100, V150, and dose homogeneity index (DHI). Biochemical relapse-free interval (bRFI) and overall survival (OS) were estimated using the Kaplan-Meier method. Cox regression evaluated associations between EQD2 D90 and outcomes. RESULTS: At median follow-up times of 108 months for bRFI and 120 months for OS, the 10-year bRFI and OS rates were 72.8% and 78.3%, respectively. In the overall cohort, EQD2 D90 was not associated with bRFI or OS. Similarly, V100, V150, and DHI were not associated with clinical outcomes. In subgroup analyses, EQD2 D90 was not associated with bRFI in any fractionation regimen. Higher EQD2 D90 was associated with improved OS in the 2-fraction subgroup but not in the 1- or 3-fraction subgroups. CONCLUSIONS: In patients treated with HDR brachytherapy monotherapy for localized prostate cancer, increasing EQD2 D90 was not associated with improved bRFI or OS. Within the relatively high and narrow dose range achieved, further increases in D90 may provide limited additional benefit once adequate target coverage is achieved, without implying equivalence between fractionation schedules. Further studies are needed to validate these findings and optimize dose delivery in HDR brachytherapy.
引用
- Muangwong P, Ostler P, Abdul-Latif M, et al. Influence of dosimetry on outcomes in HDR prostate brachytherapy monotherapy. Radiother Oncol. 2026. PMID: 42800677. doi:10.1016/j.radonc.2026.111799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。